NoteIntracellular observation of nanocarriers modified with a mitochondrial targeting signal peptide
References (20)
Mitochondria: dynamic organelles in disease, aging, and development
Cell
(2006)Mitochondrial disease
Lancet
(2006)- et al.
Newly developed strategies for multifunctional mitochondria-targeted agents in cancer therapy
Drug Discov. Today
(2011) - et al.
Mitochondrial drug delivery systems for macromolecule and their therapeutic application to mitochondrial diseases
Adv. Drug Deliv. Rev.
(2008) - et al.
Delivery of drugs and macromolecules to mitochondria
Adv. Drug Deliv. Rev.
(2007) The protein import system of mitochondria
J. Biol. Chem.
(1996)- et al.
PNPASE regulates RNA import into mitochondria
Cell
(2010) - et al.
Enhancement in selective mitochondrial association by direct modification of a mitochondrial targeting signal peptide on a liposomal based nanocarrier
Mitochondrion
(2013) - et al.
Dual function MITO-Porter, a nano carrier integrating both efficient cytoplasmic delivery and mitochondrial macromolecule delivery
Mol. Ther.
(2011) - et al.
Multifunctional envelope-type nano device (MEND) for organelle targeting via a stepwise membrane fusion process
Methods Enzymol.
(2012)
Cited by (24)
The current perspectives of nanoparticles in cellular and organ-specific drug targeting in biological system
2018, Nanostructures for the Engineering of Cells, Tissues and Organs: From Design to ApplicationsA Dual-Ligand Liposomal System Composed of a Cell-Penetrating Peptide and a Mitochondrial RNA Aptamer Synergistically Facilitates Cellular Uptake and Mitochondrial Targeting
2016, Journal of Pharmaceutical SciencesCitation Excerpt :Collectively, the RP/R8-modified MITO-Porter accumulates in mitochondria at a 4-fold higher level than the R8-modified MITO-Porter, suggesting that the dual-ligand–modified MITO-Porter facilitates cellular uptake and mitochondrial targeting more efficiently than the R8-modified MITO-Porter. The results presented here constitute the first report of the use of a mitochondrial RNA aptamer–modified nanocarrier system to regulate intracellular trafficking, although lipophilic and cationic peptide-based mitochondrial targeting have been reported in previous studies.12,19,33-35 In this study, we determined the optimal dual-ligand system for a nanocarrier for achieving efficient cellular uptake and mitochondrial targeting (RP/R8-modified MITO-Porter).
Validation of a Strategy for Cancer Therapy: Delivering Aminoglycoside Drugs to Mitochondria in HeLa Cells
2016, Journal of Pharmaceutical SciencesMultifunctional envelope-type nano device for controlled intracellular trafficking and selective targeting in vivo
2014, Journal of Controlled ReleaseCitation Excerpt :Moreover, we packaged MTS-modified MITO-Porter with outer R8-modified envelopes to construct a DF-MTS-MITO-Porter. Intracellular trafficking analysis showed that the mitochondrial targeting of the DF-MTS-MITO-Porter was enhanced compared with that of DF-R8-MITO-Porter [71]. As is well known, MTS selectively imports the original protein into mitochondria in living cells.
A nanocarrier system for the delivery of nucleic acids targeted to a pancreatic beta cell line
2014, BiomaterialsCitation Excerpt :We recently developed a MEND, consisting of a condensed pDNA core and lipid envelopes [10,11], the surface of which was modified with high-density R8, an artificially designed cell penetrating peptide [20,22], to produce the R8-MNED. A previous report showed that high-density R8-modified carriers were internalized primarily via macropinocytosis rather than clathrin-mediated endocytosis, as is the case of cationic LPs [23,24]. Moreover, the R8-MEND showed transfection activities in dividing cells that were as high as that for adenovirus [12].
Multifunctional Enveloped Nanodevices (MENDs)
2014, Advances in GeneticsCitation Excerpt :We also coated the MTS-MITO-Porter with outer R8-modified envelopes to construct a DF-MTS-MITO-Porter. Intracellular observations showed that the mitochondrial targeting of the DF-MTS-MITO-Porter was enhanced compared with that of DF-R8-MITO-Porter (Kawamura, Yamada, Yasuzaki, Hyodo, & Harashima, 2013) (Figure 6.8(C)). More recently, we evaluated the utility of mitochondrial targeting functional peptides as a ligand for delivering carriers using isolated mitochondria, homogenate, and living cells.
- †
The first two authors contributed equally to this work.